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commentaries
plasma cells in the GCs (Figure 2B). These
two events may synergize and lead to higher
levels of SIV-specific antibodies. A detailed
analysis of the cellular components expressing PD-1 and its ligands needs to be performed in the GCs of SIV-infected animals
to clarify the cellular components involved
in PD-1 blockade.
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Concluding remarks
There is a need to develop innovative therapeutic strategies to ameliorate responses
to common vaccination antigens in HIV-1–
infected children and adults (3, 6), since
limited access to ART and fast progression
to AIDS upon HIV-1 infection in developing countries impairs responses to vaccination with bacterial and viral antigens in
HIV-1–infected subjects. The present study
from Titanji and colleagues (3) paves the
way for a new treatment intervention, based
on PD-1 blockade, that aims to ameliorate
B cell responses. By reducing T cell exhaustion (17) and by improving B cell responses
(3), this PD-1–based approach may provide
a platform to accelerate immune reconstitution during HIV-1 infection.
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Patients suffering from sustained acute or chronic illness often have
decreased white blood cell and platelet counts as well as anemia, and
bone marrow studies routinely show only decreased numbers of blood
precursor cells. While much has been recently learned about the cause
of isolated anemia, the pathogenesis of true bone marrow failure (i.e.,
low bone marrow cellularity and low counts in multiple blood lineages)
has remained elusive. In this issue of the JCI, Chen et al. present evidence that overactivation of mammalian target of rapamycin signaling
in HSCs is found in two mouse models of bone marrow failure, and they
show that treatment with rapamycin significantly normalizes the low
blood counts.
Conflict of interest: The authors have declared that no
conflict of interest exists.
Citation for this article: J Clin Invest. doi:10.1172/
JCI45060.

The recent explosions in genomics and systems biology highlight the usefulness of
mathematic techniques, such as differential
equations and linear algebra, for the manipThe Journal of Clinical Investigation

http://www.jci.org

ulation and analysis of large data sets. One
powerful mathematical concept for simplifying and understanding such complex
systems is the eigenvalue, a dominant vector within a complex linear system, around
which other vectors rotate and relate. The
effects of an eigenvalue explain and dominate those of others in the system.
The concept of the eigenvalue has important implications beyond mathematical models. It is especially important in experimental
biology and clinical medicine, as investigators search for single molecules or pathways
whose effects dominate complex reactions
within a cell. Even if we do not always have at
hand detailed mathematical models and thus
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cannot always strictly identify eigenvalues a
priori, specific pharmacologic interventions
can sometimes reveal them experimentally,
thereby simplifying an otherwise bewildering
network of interacting pathways.
In this issue of the JCI, Chen et al. (1),
provide us with an intriguing example of a
biological eigenvalue unveiled by pharmacologic manipulation. They present compelling evidence linking acute and chronic
activation of the innate immune system to
suppression of HSC differentiation. They
go on to identify the mammalian target of
rapamycin (mTOR) pathway as a dominant
signal transduction pathway mediating this
effect. These results link chronic inflammation with stem cell aging and, furthermore,
make the powerful suggestion that treatment with the mTOR inhibitor rapamycin
might mitigate these effects.
Hematopoiesis is regulated
by the immune system:
growth factors and cytokines
Ever since MHC class II antigens were found
to be expressed on early myeloid progenitor
cells as well as traditional antigen-presenting
cells (2), the hematopoietic system has been
appreciated as a potential regulator and target of adaptive immune activity. Indeed, T
cells activated via engagement of their TCRs
and costimulatory molecules by activating cells (perhaps including hematopoietic
progenitors themselves) promote myeloid
differentiation through the secretion of
GM-CSF and IL-3, resulting in increased
neutrophil and red blood cell production
from HSCs, both under basal conditions
and after stem cell transplantation (3, 4).
In this issue of the JCI, Chen et al. (1) show
that extremely high levels of activation of
the innate immune system, either through
the global inactivation of the gene encoding
forkhead box P3 (FoxP3) in scurfy mice or by
injection of LPS, severely abrogate HSC differentiation, resulting in profound loss of B
lymphoid, neutrophilic, and erythropoietic
lineages. These effects could be largely prevented through inhibition of TNF-a, IL-6,
and CCL2 (but not IFN-g). Chen and colleagues went on to show that both TNF-a
and IL-6 induce phosphorylation of the
mTOR target ribosomal protein S6 kinase
(S6K) in HSCs (1). Perhaps most remarkably,
inhibition of the mTOR pathway with rapamycin largely ameliorated these suppressive
effects in both mouse models. Clearly, innate
immune activation involves the action of
multiple soluble cytokines and insoluble
ligand-receptor interactions, which in turn

trigger multiple cellular pathways, of which
mTOR is only one. However, mTOR in HSCs
must act as a “biological eigenvalue,” coordinating most of the inhibitory effects in HSCs
of this complex set of intracellular responses
to external signals of innate immune activation. Thus, while TNF-a, IL-6, and CCL2
activate multiple signal transduction pathways within target cells, not the mTOR pathway alone, the striking effects of rapamycin
demonstrate that among these pathways,
mTOR plays an integrating, dominant role,
at least within early hematopoietic cells.
High levels of TNF-α cause
overt HSC damage
How mTOR activation prevents HSCs
from proliferating and differentiating to
produce mature blood cells is less clear but
appears likely to be the result of direct stem
cell toxicity via unclear mechanisms. Chen
et al. found that the number of bone marrow cells expressing the cell surface proteins
that typically appear on HSCs actually rose
slightly, even while hematopoiesis declined,
but many of these HSCs were dead or dying
(1). Thus, the apparent increase in cells
bearing HSC markers is likely to be an artifact of the stress induced by the acute toxicity of high levels of activation of the innate
immune system, which includes high levels
of circulating cytokines.
Direct damage of HSCs might underlie
recent findings from other laboratories
that, like TNF-a, chronic IFN stimulation causes an apparent increase in cells
detected as expressing markers of HSCs
but a decrease in HSC function. This artifact is most clear in the case of IFN-induced
increases in the number of Sca-1+ckit–lin–
cells (the traditional cell surface signature
of HSCs) that were determined to occur
not because HSCs proliferate but, instead,
because cell surface expression of Sca-1 was
directly induced on Sca-1– non-HSCs (5, 6).
Cell surface Sca-1 has also been demonstrated to be induced on previously Sca-1–
hematopoietic cells by TNF-a (7), and this
might at least partially explain the findings of Chen et al. (1). Whether alterations
in cell surface proteins other than Sca-1
can explain the apparent lack of increase in
hematopoiesis despite increased numbers
of cells apparently marking as HSCs in the
paper by Chen et al. (1) is not clear, but it
is clearly possible. In any case, the results
of Chen and colleagues make it clear that
direct cell damage can readily be detected
on early hematopoietic cells (1), which
include both HSCs and slightly more difThe Journal of Clinical Investigation
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ferentiated non-HSCs. Most importantly,
no study has yet shown an increase in the
number of functional, transplantable
HSCs after exposure to cytokine mediators
of inflammation, including IFN, TNF-a,
and IL-6, i.e., numbers of cells with a particular cell surface phenotype do not equal
numbers of functional stem cells. Limiting
dilution transplantation experiments to
quantitatively probe this possibility would
be very interesting. But whether cells marking as HSCs increase in number or not after
extremely high levels of activation of the
innate immune system, the important point
is that from a functional point of view, they
are not able to fend off the powerful effects
of the innate immune system on HSC integrity and differentiation capacity, irrespective
of stem cell cycling per se.
mTOR, rapamycin, and
the complications of innate
immune activation
Whether or not it is true that HSC numbers
rise, the significance of functional hematopoietic suppression by mediators of inflammation is real enough. The findings of Chen
et al. (1) will clearly intrigue every clinician
who has cared for severely ill patients, often
in intensive care units, whose pancytopenia
defies both explanation and treatment. Perhaps, as suggested by Chen et al. (8), mTOR
inhibition acts to prevent premature stem
cell aging and exhaustion induced under the
veil of innate immune activation. The possibility that short-term rapamycin treatment
could ameliorate this and perhaps other
manifestations of pathologic cytokine activation should inspire careful clinical trials
in the future. Such trials will exemplify the
clinical investigator’s understanding and
application of eigenvalues, both mathematical and biological, to the untangling of the
complex web of the cell for the understanding and treatment of disease.
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Adaptation to hypoxia is an essential cellular response controlled by the oxygen-sensitive master transcription factor hypoxia-inducible factor 1 (HIF-1).
HIF-1 expression is also controlled by specific microRNAs and, in turn,
controls the expression of other microRNAs, which fine-tune adaptation to
low oxygen tension. In this issue of the JCI, Ghosh and colleagues identify a
unique microRNA in hypoxic endothelial cells, miR424, that promotes HIF-1
stabilization and angiogenesis. The actions of this microRNA are considered in the context of the complex interactions that act to ensure optimal
endothelial adaptation to this critical environmental condition.
Adaptation to hypoxia is an essential
homeostatic mechanism in mammalian
cells. Hypoxia can occur not only as a global
consequence of low atmospheric oxygen tension, but also locally at sites of inflammation, tissue ischemia and injury, and solid
tumor growth. Fundamental mechanisms
have, therefore, evolved by which cells adapt
to hypoxic conditions and their potentially
adverse consequences, both acutely and
chronically, in health and disease.
Among the key responses to acute hypoxia is the upregulation of hypoxia-inducible
factors (HIFs), master transcription factors
that induce the highly conserved expression of many genes (likely more than 100)
and are responsible for the majority of the
hypoxic program in metazoan cells (1). The
prototypical HIF is a heterodimer of α and
β subunits. Under normoxic conditions, the
α subunit is rapidly hydroxylated at specific
prolyl residues by prolyl hydroxylase domain
(PHD) proteins. Upon hydroxylation, the α
subunit is recognized by the von Hippel–
Lindau protein and consequently undergoes rapid proteasomal degradation. Under
Conflict of interest: The author has declared that no
conflict of interest exists.
Citation for this article: J Clin Invest. doi:10.1172/
JCI45105.

hypoxic conditions, however, the α subunit
does not undergo prolyl hydroxylation and,
as a result, forms a stable complex with the
β subunit, which binds as a heterodimer to
hypoxia response elements (HREs) in the
promoter regions of hypoxia-sensitive genes
to induce gene transcription. HIF-dependent transcriptional changes lead to a broad
range of cellular adaptations, including metabolic, proliferative, apoptotic, and angiogenic. In higher metazoans, three different
HIF-α proteins have been identified: HIF-1α
and HIF-2α have some transcriptional targets in common and some that are unique to
each subunit, while splice variants of HIF-3α
have dominant negative effects on HIFdependent gene transcription (2, 3).
MicroRNAs and transcriptional
tuning
MicroRNA molecules (miRNAs) are essential,
noncanonical RNA species of 18–23 nucleotides in length that regulate gene expression.
There are believed to be more than 1,000
miRNA genes in the human genome, which
are estimated to regulate more than onethird of all mRNA transcripts (4). As part of
the RNA-induced silencing complex (RISC),
miRNAs negatively regulate gene transcription by annealing to the 3′ untranslated
region of specific mRNA targets to repress
The Journal of Clinical Investigation
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translation, enhance mRNA degradation,
or both. In contrast to the promoter-based
catalytic amplification of mRNA synthesis,
miRNAs are viewed as weak modulators of
the transcriptional response, fine-tuning
gene expression largely by negative regulation in a process that requires stoichiometric
binding to mRNA targets (5).
Hypoxamirs: microRNAs
induced by hypoxia
Hypoxia has recently been shown to induce
the expression of a number of miRNAs,
which have been termed “hypoxamirs” (6).
Owing to the central importance of HIFs to
the hypoxic response, its potent regulation
of many genes whose expression is regulated
by oxygen tension, and the significant number of hypoxamirs, it is logical to explore the
relationships among HIFs and hypoxamirs in
order to understand better the complex regulation of the hypoxic program in metazoans.
From the perspective of the miRNA
response to hypoxia, miRNAs can be viewed
as comprising three groups (Table 1): first,
those induced by HIFs under hypoxic conditions (HIF-dependent hypoxamirs); second, those induced by hypoxia that, in turn,
affect expression of HIF; third, those whose
expression is not dependent on hypoxia but
that affect HIF expression. The number of
hypoxamirs that have been identified in
each of these groups is expanding rapidly,
illustrating the extraordinary regulatory
complexity of the hypoxic program and the
importance of considering that program in
a holistic, system-based context. In this issue
of the JCI, Ghosh and colleagues (7) identify
a new hypoxamir, miR424, that affects HIF
expression. This report is unique for three
reasons: it is the first demonstration of the

